ASX:IBX

Imagion Biosystems Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume10.77 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Imagion Biosystems (ASX:IBX) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying IBX stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Imagion Biosystems, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

(BUX) (CNSX:BUX) and Imagion Biosystems (ASX:IBX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares (BUX) and Imagion Biosystems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A

(BUX) has higher earnings, but lower revenue than Imagion Biosystems.

Profitability

This table compares (BUX) and Imagion Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
Imagion BiosystemsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for (BUX) and Imagion Biosystems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
Imagion Biosystems0000N/A

Summary

Imagion Biosystems beats (BUX) on 1 of the 1 factors compared between the two stocks.

12144 (CNSX:IME) and Imagion Biosystems (ASX:IBX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares 12144 and Imagion Biosystems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A

12144 has higher earnings, but lower revenue than Imagion Biosystems.

Profitability

This table compares 12144 and Imagion Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
Imagion BiosystemsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for 12144 and Imagion Biosystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
Imagion Biosystems0000N/A

Summary

Imagion Biosystems beats 12144 on 1 of the 1 factors compared between the two stocks.

Imagion Biosystems (ASX:IBX) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Imagion Biosystems and BARD1 Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

BARD1 Life Sciences has lower revenue, but higher earnings than Imagion Biosystems.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Imagion Biosystems and BARD1 Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Imagion Biosystems0000N/A
BARD1 Life Sciences0000N/A

Profitability

This table compares Imagion Biosystems and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Imagion BiosystemsN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Summary

Imagion Biosystems beats BARD1 Life Sciences on 2 of the 3 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and Imagion Biosystems (ASX:IBX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Charles River Laboratories International and Imagion Biosystems' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A

Charles River Laboratories International has higher earnings, but lower revenue than Imagion Biosystems.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Charles River Laboratories International and Imagion Biosystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
Imagion Biosystems0000N/A

Profitability

This table compares Charles River Laboratories International and Imagion Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
Imagion BiosystemsN/AN/AN/A

Summary

Imagion Biosystems beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Imagion Biosystems (ASX:IBX) and Cryosite (ASX:CTE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Imagion Biosystems and Cryosite's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A
Cryosite$9.71 million0.00$515,455.60A$0.01N/A

Cryosite has higher revenue and earnings than Imagion Biosystems.

Analyst Ratings

This is a breakdown of current ratings for Imagion Biosystems and Cryosite, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Imagion Biosystems0000N/A
Cryosite0000N/A

Profitability

This table compares Imagion Biosystems and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Imagion BiosystemsN/AN/AN/A
CryositeN/AN/AN/A

Summary

Cryosite beats Imagion Biosystems on 3 of the 3 factors compared between the two stocks.

Imagion Biosystems (ASX:IBX) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Imagion Biosystems and dorsaVi's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imagion Biosystems$2.70 million0.00$-7,253,610.11A($0.01)N/A
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A

dorsaVi has lower revenue, but higher earnings than Imagion Biosystems.

Profitability

This table compares Imagion Biosystems and dorsaVi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Imagion BiosystemsN/AN/AN/A
dorsaViN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Imagion Biosystems and dorsaVi, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Imagion Biosystems0000N/A
dorsaVi0000N/A

Summary

Imagion Biosystems beats dorsaVi on 2 of the 3 factors compared between the two stocks.


Imagion Biosystems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$12.39flat$0.00N/A0.00Gap Up
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00Gap Up
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$469.80flat$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.05flat$0.00N/A0.00Decrease in Short Interest
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00Gap Down
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.